CoChat

Notch activation inhibits AML growth and survival: a potential therapeutic approach

Open access

The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.

Abstract

Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20121527

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Notch pathway expression in human AML patient samples. (A) Heatmap for Notch1–4, HES1, and Deltex1 (DTX1) from Affymetrix HG-U133 Plus 2 microarray data from 344 AML patient samples, 11 normal CD34-selected controls, and 8 T-ALL patient samples, normalized and shown as log2 scale (red, high; green, low). (B) Box plots from data in A. A, AML patient samples; C, CD34-selected controls; T, T-ALL patient samples. Student’s t tests reveal significant differences between AML and T-ALL samples in all four Notch receptors and two target genes (HES1 and Deltex1); bars indicate P < 0.001. A single dataset was analyzed. (C) Column chart showing cleaved Notch1/2 receptor antibody (Val1744; Cell Signaling Technology) data from a validated reverse phase protein lysate array (RPPA) with quantitative dilutions of 560 AML patient samples, 10 normal CD34-selected controls, and 21 normal peripheral blood mononuclear cell controls (mean ± SD). (D) Box plots from RPPA in C showing average and SD for FAB subtypes. Single dataset analyzed.
Figure 1. Notch pathway expression in human AML patient samples. (A) Heatmap for Notch1–4, HES1, and Deltex1 (DTX1) from Affymetrix HG-U133 Plus 2 microarray data from 344 AML patient samples, 11 normal CD34-selected controls, and 8 T-ALL patient samples, normalized and shown as log2 scale (red, high; green, low). (B) Box plots from data in A. A, AML patient samples; C, CD34-selected controls; T, T-ALL patient samples. Student’s t tests reveal significant differences between AML and T-ALL samples in all four Notch receptors and two target genes (HES1 and Deltex1); bars indicate P < 0.001. A single dataset was analyzed. (C) Column chart showing cleaved Notch1/2 receptor antibody (Val1744; Cell Signaling Technology) data from a validated reverse phase protein lysate array (RPPA) with quantitative dilutions of 560 AML patient samples, 10 normal CD34-selected controls, and 21 normal peripheral blood mononuclear cell controls (mean ± SD). (D) Box plots from RPPA in C showing average and SD for FAB subtypes. Single dataset analyzed.CC BY-NC-SA · PubMed Central
Figure 2. Notch pathway expression in human AML lines. (A) mRNA expression of Notch1–4 by QRT-PCR. Asterisk denotes lack of Notch2 mRNA in K562 line. (B) mRNA expression of Notch target gene HES1 in T-ALL and AML lines by QRT-PCR. Log scale was used, and triplicate samples were analyzed. (C) Immunoblot of AML and T-ALL lines probed for Notch1, Notch2, cleaved Notch1/2, and β-actin. Asterisk denotes K562 line with undetectable Notch2 protein expression. Representative of three blots. (D) Immunoblot of AML and T-ALL lines probed for Notch ligands Jagged1 and DLL1, as well as cleaved Notch1/2 and β-actin. Representative of two blots. (E) Flow cytometry data for Notch1 and Notch2 cell surface expression on AML and T-ALL lines, normalized to isotype controls in each cell line (log scale; mean ± SD). Triplicate samples analyzed.
Figure 2. Notch pathway expression in human AML lines. (A) mRNA expression of Notch1–4 by QRT-PCR. Asterisk denotes lack of Notch2 mRNA in K562 line. (B) mRNA expression of Notch target gene HES1 in T-ALL and AML lines by QRT-PCR. Log scale was used, and triplicate samples were analyzed. (C) Immunoblot of AML and T-ALL lines probed for Notch1, Notch2, cleaved Notch1/2, and β-actin. Asterisk denotes K562 line with undetectable Notch2 protein expression. Representative of three blots. (D) Immunoblot of AML and T-ALL lines probed for Notch ligands Jagged1 and DLL1, as well as cleaved Notch1/2 and β-actin. Representative of two blots. (E) Flow cytometry data for Notch1 and Notch2 cell surface expression on AML and T-ALL lines, normalized to isotype controls in each cell line (log scale; mean ± SD). Triplicate samples analyzed.CC BY-NC-SA · PubMed Central
Figure 3. Activated Notch1–4 induce growth arrest and increase HES1 expression in AML cell lines. (A) Flow cytometry data showing changes in GFP when eight AML lines are transduced with retroviral vectors expressing either activated ICN1, the Notch inhibitor dnMAML, or GFP-only control (mean ± SD). Because of differences in transduction efficiency, all experiments were normalized to day 2 levels. Triplicate samples were analyzed. (B) Flow cytometry–based cell cycle analysis via the DNA dye DRAQ5 in U937 AML cells. DNA content of GFP+ (ICN1-transduced) cells are compared to GFP− (untransduced) cells 48 hours after transduction. FlowJo software was used to estimate the percentage of cells in the G0/G1, S, and G2/M phases of the cell cycle. Triplicate samples were analyzed, and similar results were obtained in K562 and HL60 lines. (C) Cell counts measured by hemocytometer. Results from replicate experiments with U937 cells were combined and normalized to day 1. ANOVA reveals significant differences across time points (P < 0.001). Triplicate samples analyzed and similar results were obtained in K562 and HL60 lines. (D) Flow cytometry data showing changes in GFP when U937 cells are transduced with constitutively active forms of Notch1–4, i.e., ICN1–4 (mean ± SD). Triplicate samples analyzed and similar results were obtained in K562 line. (E) Immunoblot of U937 AML cells transduced with GFP, HES1, and ICN1–4, and then probed for GFP, HES1, and β-actin. Representative of two blots.
Figure 3. Activated Notch1–4 induce growth arrest and increase HES1 expression in AML cell lines. (A) Flow cytometry data showing changes in GFP when eight AML lines are transduced with retroviral vectors expressing either activated ICN1, the Notch inhibitor dnMAML, or GFP-only control (mean ± SD). Because of differences in transduction efficiency, all experiments were normalized to day 2 levels. Triplicate samples were analyzed. (B) Flow cytometry–based cell cycle analysis via the DNA dye DRAQ5 in U937 AML cells. DNA content of GFP+ (ICN1-transduced) cells are compared to GFP− (untransduced) cells 48 hours after transduction. FlowJo software was used to estimate the percentage of cells in the G0/G1, S, and G2/M phases of the cell cycle. Triplicate samples were analyzed, and similar results were obtained in K562 and HL60 lines. (C) Cell counts measured by hemocytometer. Results from replicate experiments with U937 cells were combined and normalized to day 1. ANOVA reveals significant differences across time points (P < 0.001). Triplicate samples analyzed and similar results were obtained in K562 and HL60 lines. (D) Flow cytometry data showing changes in GFP when U937 cells are transduced with constitutively active forms of Notch1–4, i.e., ICN1–4 (mean ± SD). Triplicate samples analyzed and similar results were obtained in K562 line. (E) Immunoblot of U937 AML cells transduced with GFP, HES1, and ICN1–4, and then probed for GFP, HES1, and β-actin. Representative of two blots.CC BY-NC-SA · PubMed Central
Figure 4. The Notch target gene HES1 induces growth arrest via its repressor domain. (A) Flow cytometry–based competitive proliferation assay showing changes in GFP after HES1 transduction in seven AML lines (mean ± SD). Triplicate samples were analyzed. (B) Flow cytometry–based assay showing changes in GFP in cells stably transduced with a tamoxifen-inducible ER-HES1 and exposed to 4-OH tamoxifen at the doses and the time durations indicated. Representative of two experiments. (C) Flow cytometry–based cell cycle histogram showing DNA content measured by propidium iodide (PI) in ER-HES1 cells exposed to 4 µM 4-OH tamoxifen for 48 h. Representative of three experiments. (D) HES1 mutants lacking either the conserved WRPW motif (HES1-GRPG) or the C-terminal repressor domain (HES1-deltaC) were constructed. (E) HES1 mutants were transduced into AML cells. A competitive proliferation assay reveals growth effects by wild-type HES1, the GRPG mutant, and the HES1-deltaC mutant (mean ± SD). **, P < 0.001. Triplicate samples analyzed and similar results were obtained in K562 and HL60 lines.
Figure 4. The Notch target gene HES1 induces growth arrest via its repressor domain. (A) Flow cytometry–based competitive proliferation assay showing changes in GFP after HES1 transduction in seven AML lines (mean ± SD). Triplicate samples were analyzed. (B) Flow cytometry–based assay showing changes in GFP in cells stably transduced with a tamoxifen-inducible ER-HES1 and exposed to 4-OH tamoxifen at the doses and the time durations indicated. Representative of two experiments. (C) Flow cytometry–based cell cycle histogram showing DNA content measured by propidium iodide (PI) in ER-HES1 cells exposed to 4 µM 4-OH tamoxifen for 48 h. Representative of three experiments. (D) HES1 mutants lacking either the conserved WRPW motif (HES1-GRPG) or the C-terminal repressor domain (HES1-deltaC) were constructed. (E) HES1 mutants were transduced into AML cells. A competitive proliferation assay reveals growth effects by wild-type HES1, the GRPG mutant, and the HES1-deltaC mutant (mean ± SD). **, P < 0.001. Triplicate samples analyzed and similar results were obtained in K562 and HL60 lines.CC BY-NC-SA · PubMed Central
Figure 5. Notch activation induces caspase-mediated apoptosis with BCL2 down-regulation, and HES1-mediated growth inhibition in AML cells is rescued by BCL2 re-expression. (A) Flow cytometry–based contour plots of AML cells transduced with ICN1–4 or HES1 or GFP-only vector and treated with the pan-caspase inhibitor ZVAD, or DMSO vehicle control. Fold increase in Annexin V MFI is noted in each graph (4–11×). Representative of two experiments, and similar results were obtained in the K562 line. (B) Immunoblot of AML cells transduced with GFP vector, ICN1, or ICN2 probed for HES1, BCL2, p53, and β-actin. Representative of two blots. (C) Immunoblot of AML and T-ALL cells transduced with GFP vector or HES1 probed for HES1, BCL2, cleaved caspase 3, cleaved PARP1, and β-actin. Representative of two blots. (D) Flow cytometry–based graph of Annexin V binding percentage in AML cells expressing GFP vector, HES1, BCL2, or HES1 + BCL2 (mean ± SD). Inset shows flow cytometry–based histograms of Annexin V binding from same experiment. Triplicate samples were analyzed and similar results were obtained in an additional cell line. (E) Competitive proliferation assay showing changes in GFP percentage after transduction with HES1, HES1 + Thy vector control, and HES1 + BCL2. Representative of two experiments.
Figure 5. Notch activation induces caspase-mediated apoptosis with BCL2 down-regulation, and HES1-mediated growth inhibition in AML cells is rescued by BCL2 re-expression. (A) Flow cytometry–based contour plots of AML cells transduced with ICN1–4 or HES1 or GFP-only vector and treated with the pan-caspase inhibitor ZVAD, or DMSO vehicle control. Fold increase in Annexin V MFI is noted in each graph (4–11×). Representative of two experiments, and similar results were obtained in the K562 line. (B) Immunoblot of AML cells transduced with GFP vector, ICN1, or ICN2 probed for HES1, BCL2, p53, and β-actin. Representative of two blots. (C) Immunoblot of AML and T-ALL cells transduced with GFP vector or HES1 probed for HES1, BCL2, cleaved caspase 3, cleaved PARP1, and β-actin. Representative of two blots. (D) Flow cytometry–based graph of Annexin V binding percentage in AML cells expressing GFP vector, HES1, BCL2, or HES1 + BCL2 (mean ± SD). Inset shows flow cytometry–based histograms of Annexin V binding from same experiment. Triplicate samples were analyzed and similar results were obtained in an additional cell line. (E) Competitive proliferation assay showing changes in GFP percentage after transduction with HES1, HES1 + Thy vector control, and HES1 + BCL2. Representative of two experiments.CC BY-NC-SA · PubMed Central
Figure 6. Notch inhibitor dnMAML enhances in vivo engraftment and increases p53/p21 levels. (A) In vivo competitive proliferation/engraftment assay: all transduced ML1 cells were sorted to 50:50 GFP+:GFP− prior to injection. Graph shows percent peripheral blood engraftment with GFP− (control) and GFP+ (transduced) cells. Mean ± SD. *, P < 0.01; **, P < 0.001; ***, P < 0.0001. (B) Graph shows percentage of human CD45+ ML1 which express GFP (mean ± SD). Dashed 50% line shows starting 50:50 mixture for all groups revealing disadvantage for ICN1, ICN2, and HES1 and significant advantage for dnMAML. Mean ± SD. *, P < 0.01; **, P < 0.001; ***, P < 0.0001. Five mice per cohort. (C) In vivo proliferation/engraftment assay: all transduced THP1 cells were sorted to >99% GFP+ prior to injection. Graph shows percent peripheral blood engraftment with GFP+ THP1 cells in peripheral blood and bone marrow (mean ± SD). (*, P < 0.01; **, P < 0.001). Five mice per cohort. (D) Flow cytometry–based histogram shows levels of intracellular p53 staining in peripheral blood GFP+ cells for GFP-vector control and dnMAML mice. MFI indicated by each layered histogram, revealing high p53 levels in control GFP cells, and lower p53 levels in dnMAML-expressing cells. Representative of three mice. (E) Immunoblot of AML cells transduced with GFP, ICN1, or ICN2 and probed for HES1, p53, cleaved caspase 3, cleaved PARP1, and β-actin. Representative of two blots. (F) Immunoblot of AML and T-ALL cells transduced with GFP or HES1 and probed for HES1, p53, and β-actin. Representative of two blots. (G) Graph showing change in mRNA levels of p21 and p27 by QRT-PCR comparing GFP and HES1-transduced AML cells. *, P < 0.01. Triplicate samples analyzed.
Figure 6. Notch inhibitor dnMAML enhances in vivo engraftment and increases p53/p21 levels. (A) In vivo competitive proliferation/engraftment assay: all transduced ML1 cells were sorted to 50:50 GFP+:GFP− prior to injection. Graph shows percent peripheral blood engraftment with GFP− (control) and GFP+ (transduced) cells. Mean ± SD. *, P < 0.01; **, P < 0.001; ***, P < 0.0001. (B) Graph shows percentage of human CD45+ ML1 which express GFP (mean ± SD). Dashed 50% line shows starting 50:50 mixture for all groups revealing disadvantage for ICN1, ICN2, and HES1 and significant advantage for dnMAML. Mean ± SD. *, P < 0.01; **, P < 0.001; ***, P < 0.0001. Five mice per cohort. (C) In vivo proliferation/engraftment assay: all transduced THP1 cells were sorted to >99% GFP+ prior to injection. Graph shows percent peripheral blood engraftment with GFP+ THP1 cells in peripheral blood and bone marrow (mean ± SD). (*, P < 0.01; **, P < 0.001). Five mice per cohort. (D) Flow cytometry–based histogram shows levels of intracellular p53 staining in peripheral blood GFP+ cells for GFP-vector control and dnMAML mice. MFI indicated by each layered histogram, revealing high p53 levels in control GFP cells, and lower p53 levels in dnMAML-expressing cells. Representative of three mice. (E) Immunoblot of AML cells transduced with GFP, ICN1, or ICN2 and probed for HES1, p53, cleaved caspase 3, cleaved PARP1, and β-actin. Representative of two blots. (F) Immunoblot of AML and T-ALL cells transduced with GFP or HES1 and probed for HES1, p53, and β-actin. Representative of two blots. (G) Graph showing change in mRNA levels of p21 and p27 by QRT-PCR comparing GFP and HES1-transduced AML cells. *, P < 0.01. Triplicate samples analyzed.CC BY-NC-SA · PubMed Central
Figure 7. Notch ligand DLL1 co-culture inhibits AML growth, induces apoptosis, down-regulates BCL2, and reveals the critical roles of HES1, BCL2, and p53 in Notch-mediated apoptosis in AML. (A) Cell counts after 72 h of co-culture on human stromal line HS5 transduced with GFP-only or Notch ligand DLL1 GFP. 100,000 AML or T-ALL cells were placed over confluent HS5-GFP or HS5-DLL1 cells. (**, P < 0.001). Triplicate samples analyzed. (B) Flow cytometry–based apoptosis assay in AML and T-ALL cells stained with Annexin V after co-culture with HS5-GFP or HS5-DLL1 cells for 24 h. **, P < 0.001. Triplicate samples were analyzed. (C) Immunoblot of AML and T-ALL cells after co-culture with HS5-GFP or HS5-DLL1 cells for 48 h. Representative of two blots. (D) mRNA expression of BCL2 in AML and T-ALL co-cultured with HS5-GFP or HS5-DLL1 cells for 24 h. **, P < 0.001. Triplicate samples analyzed. (E) Flow cytometry–based apoptosis assay of AML cells transfected with siRNA to HES1 or control, and then co-cultured on HS5-GFP or HS5-DLL1 for 48 h. Representative of two experiments. (F) Immunoblot showing effect of transfection with siRNA to HES1 on level of HES1 protein induced by transduction with ICN1. Representative of two blots. (G) Flow cytometry–based apoptosis assay of AML cells transfected with BCL2, siP53, or BCL2 + siP53 was then co-cultured on HS5-GFP or HS5-DLL1 for 48 h. Representative of two experiments.
Figure 7. Notch ligand DLL1 co-culture inhibits AML growth, induces apoptosis, down-regulates BCL2, and reveals the critical roles of HES1, BCL2, and p53 in Notch-mediated apoptosis in AML. (A) Cell counts after 72 h of co-culture on human stromal line HS5 transduced with GFP-only or Notch ligand DLL1 GFP. 100,000 AML or T-ALL cells were placed over confluent HS5-GFP or HS5-DLL1 cells. (**, P < 0.001). Triplicate samples analyzed. (B) Flow cytometry–based apoptosis assay in AML and T-ALL cells stained with Annexin V after co-culture with HS5-GFP or HS5-DLL1 cells for 24 h. **, P < 0.001. Triplicate samples were analyzed. (C) Immunoblot of AML and T-ALL cells after co-culture with HS5-GFP or HS5-DLL1 cells for 48 h. Representative of two blots. (D) mRNA expression of BCL2 in AML and T-ALL co-cultured with HS5-GFP or HS5-DLL1 cells for 24 h. **, P < 0.001. Triplicate samples analyzed. (E) Flow cytometry–based apoptosis assay of AML cells transfected with siRNA to HES1 or control, and then co-cultured on HS5-GFP or HS5-DLL1 for 48 h. Representative of two experiments. (F) Immunoblot showing effect of transfection with siRNA to HES1 on level of HES1 protein induced by transduction with ICN1. Representative of two blots. (G) Flow cytometry–based apoptosis assay of AML cells transfected with BCL2, siP53, or BCL2 + siP53 was then co-cultured on HS5-GFP or HS5-DLL1 for 48 h. Representative of two experiments.CC BY-NC-SA · PubMed Central
Figure 8. Notch agonist peptide induces apoptosis in AML cell lines and patient samples. (A) A 17-aa peptide derived from the human Jagged1 DSL domain is shown (DSL). A mutant with two cysteines replaced by serines (DSL mutant) is also shown. (B) Dose−response curves after 48-h exposure to DSL peptide for AML lines (HL60, KG1) and nonhematopoietic line HEK-293. alamarBlue staining was used to measure percent viability of cells after exposure to peptide. Mean ± SD, ANOVA; **, P < 0.001. Triplicate samples were analyzed and are representative of two experiments. (C) Dose response curves after 48 h exposure to DSL and DSL mutant peptides for U937 cells, with percentage of apoptosis measured by Annexin V binding. Mean ± SD, ANOVA **, P < 0.001. Triplicate samples were analyzed and are representative of two experiments. (D) Immunoblot showing induction of cleaved Notch receptors and HES1 expression in AML lines after 24 h of exposure to the DSL peptide. Representative of two blots. (E) The effect of GSI on DSL-mediated apoptosis (**, P < 0.001). Triplicate samples analyzed. (F) Human AML lines treated for 48 h with DSL peptide, DSL mutant peptide, or vehicle control. (**, P < 0.001). Triplicate samples were analyzed. (G) Primary human AML patient samples (Table 2) treated for 48 h with DSL peptide, DSL mutant peptide, or vehicle control. Mean ± SD; **, P < 0.001; ***, P < 0.0001. Triplicate samples were analyzed.
Figure 8. Notch agonist peptide induces apoptosis in AML cell lines and patient samples. (A) A 17-aa peptide derived from the human Jagged1 DSL domain is shown (DSL). A mutant with two cysteines replaced by serines (DSL mutant) is also shown. (B) Dose−response curves after 48-h exposure to DSL peptide for AML lines (HL60, KG1) and nonhematopoietic line HEK-293. alamarBlue staining was used to measure percent viability of cells after exposure to peptide. Mean ± SD, ANOVA; **, P < 0.001. Triplicate samples were analyzed and are representative of two experiments. (C) Dose response curves after 48 h exposure to DSL and DSL mutant peptides for U937 cells, with percentage of apoptosis measured by Annexin V binding. Mean ± SD, ANOVA **, P < 0.001. Triplicate samples were analyzed and are representative of two experiments. (D) Immunoblot showing induction of cleaved Notch receptors and HES1 expression in AML lines after 24 h of exposure to the DSL peptide. Representative of two blots. (E) The effect of GSI on DSL-mediated apoptosis (**, P < 0.001). Triplicate samples analyzed. (F) Human AML lines treated for 48 h with DSL peptide, DSL mutant peptide, or vehicle control. (**, P < 0.001). Triplicate samples were analyzed. (G) Primary human AML patient samples (Table 2) treated for 48 h with DSL peptide, DSL mutant peptide, or vehicle control. Mean ± SD; **, P < 0.001; ***, P < 0.0001. Triplicate samples were analyzed.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 58 references

Cited by

See all 152

Metadata

Authors
Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., Melnick, A. M., Figueroa, M. E., & Zweidler-McKay, P. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Department of Pediatric Hematology/Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL 32806 4
  • Cook Children's Medical Center (US)
  • Sigma Genosys (United States) (US)
  • Weill Cornell Medicine (US)
  • Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48109 8
  • Division of Pediatrics 1 , 2 , and 3
Venue
Journal of Experimental Medicine
Published
2013-01-28
Volume
210
Issue
2
Pages
321-337
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2113096952
Cited by
152
References
59
Citations by year
2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 8 · 2020: 8 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 15 · 2015: 18 · 2014: 20 · 2013: 10
FWCI
15.06
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA138816, P30CA016672)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
Keywords
Notch signaling, acute myeloid leukemia, Notch1, Notch2, Notch3, Notch4, Hes1, apoptosis, Bcl-2, therapeutic target
MeSH terms
Transcription Factor HES-1, Adolescent, Animals, Cell Survival, Child, DNA-Binding Proteins, Humans, Infant, Mutation, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Signal Transduction, Leukemia, Myeloid, Acute, Gene Expression, Tumor Suppressor Protein p53, Mice, SCID, Mice, Inbred NOD, Apoptosis, Mice, Knockout, Homeodomain Proteins, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Receptors, Notch

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.